April 3, 2020 -- Serimmune has used its immune mapping technology on clinical and preclinical samples provided by Merck.
The collaboration included Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to help identify antigens that stimulate immunity. The goal is to develop and commercialize promising agents.
Serimmune can receive payments related to research, development, and regulatory milestones as well as tiered royalty payments on sales arising from products that result from the partnership, the company noted.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: